Tau PET Imaging in Atypical Dementias
Overview
- Phase
- Phase 1
- Intervention
- 18F-AV-1451
- Conditions
- Primary Progressive Aphasia With Suspected Alzheimer's Disease
- Sponsor
- University of Chicago
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Tau levels in PPA participants
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have primary progressive aphasia
Exclusion Criteria
- •Pregnancy
- •Breastfeeding
- •Receiving radiation clinically
Arms & Interventions
AV-1451 Recipients
Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
Intervention: 18F-AV-1451
AV-1451 Recipients
Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
Intervention: PET
Outcomes
Primary Outcomes
Tau levels in PPA participants
Time Frame: 2 years
Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.